Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of pharmacokinetics and pharmacodynamics of Mylan's insulin glargine with Lantus in type 1 diabetes patients

Next Previous
X
Search
Trial Profile

Comparison of pharmacokinetics and pharmacodynamics of Mylan's insulin glargine with Lantus in type 1 diabetes patients

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics; Pharmacokinetics
  • Acronyms GLARGCT100111

    • Most Recent Events

    • 22 Jul 2017 Primary endpoint (Pharmacodynamic endpoint: GIR max) has been met, according to the results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 22 Jul 2017 Primary endpoint (Pharmacodynamic endpoint: AUC GIR 0-30 h:AUCGIR) has been met, according to results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 22 Jul 2017 Primary endpoint (C ins max (maximum INS).) has been met, according to the results presented at the 77th Annual Scientific Sessions of the American Diabetes Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top